These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327 [TBL] [Abstract][Full Text] [Related]
5. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288 [TBL] [Abstract][Full Text] [Related]
7. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies. Lam MC; Bressler B Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118 [TBL] [Abstract][Full Text] [Related]
8. Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease. Wyant T; Yang L; Lirio RA; Rosario M J Clin Pharmacol; 2021 Sep; 61(9):1174-1181. PubMed ID: 33908636 [TBL] [Abstract][Full Text] [Related]
9. Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis. Perry C; Fischer K; Elmoursi A; Kern C; Currier A; Kudaravalli P; Akanbi O; Tripathi N; Yarra P; Su L; Flomenhoft D; Stromberg A; Barrett TA Dig Dis Sci; 2021 Jun; 66(6):2051-2058. PubMed ID: 32710192 [TBL] [Abstract][Full Text] [Related]
10. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Feagan BG; Patel H; Colombel JF; Rubin DT; James A; Mody R; Lasch K Aliment Pharmacol Ther; 2017 Jan; 45(2):264-275. PubMed ID: 27859410 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. Yajnik V; Khan N; Dubinsky M; Axler J; James A; Abhyankar B; Lasch K Adv Ther; 2017 Feb; 34(2):542-559. PubMed ID: 28070861 [TBL] [Abstract][Full Text] [Related]
13. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123 [TBL] [Abstract][Full Text] [Related]
14. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. Sandborn WJ; Colombel JF; Panaccione R; Dulai PS; Rosario M; Cao C; Barocas M; Lasch K J Crohns Colitis; 2019 Feb; 13(2):172-181. PubMed ID: 30285104 [TBL] [Abstract][Full Text] [Related]
15. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. Motoya S; Watanabe K; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T PLoS One; 2019; 14(2):e0212989. PubMed ID: 30807613 [TBL] [Abstract][Full Text] [Related]
16. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis. Noman M; Ferrante M; Bisschops R; De Hertogh G; Van den Broeck K; Rans K; Rutgeerts P; Vermeire S; Van Assche G J Crohns Colitis; 2017 Sep; 11(9):1085-1089. PubMed ID: 28369329 [TBL] [Abstract][Full Text] [Related]